Who
Martine Zimmermann
Director
Company insider
Files Form 4 as: Director, Ligand Pharmaceuticals; Director, Candel Therapeutics.
In numbers
- Trades disclosed
- 20
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $684K
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 22 Sep 2023
- Last trade
- 22 Sep 2026
- Last filed
- 24 Sep 2026
Companies traded
Activity over time
1 Sep – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Sep 2026filed 24 Sep 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $34K115 at $298.50 | filing |
| 22 Sep 2026filed 24 Sep 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $34K115 at $298.50 | filing |
| 10 Sep 2026filed 14 Sep 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $342K1,200 at $285.00 | filing |
| 10 Sep 2026filed 14 Sep 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $342K1,200 at $285.00 | filing |
| 8 Sep 2026filed 10 Sep 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,000 at $0.00 | filing |
| 8 Sep 2026filed 10 Sep 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —836 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $43K182 at $237.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,938 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,938 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —836 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $43K182 at $237.00 | filing |
| 22 Sep 2025filed 24 Sep 2025 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $20K115 at $170.77 | filing |
| 6 Jun 2025filed 10 Jun 2025 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,783 at $0.00 | filing |
| 6 Jun 2025filed 10 Jun 2025 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,209 at $0.00 | filing |
| 6 Jun 2025filed 10 Jun 2025 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $20K188 at $105.99 | filing |
| 14 Jun 2024filed 18 Jun 2024 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,444 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,252 at $0.00 | filing |
| 22 Sep 2023filed 26 Sep 2023 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,345 at $0.00 | filing |
| 22 Sep 2023filed 26 Sep 2023 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —2,285 at $0.00 | filing |
News
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directorsfinanznachrichten.de · 10 Sep 2026
1 headline in the last 90 days name Martine Zimmermann; 0 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.